|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
|
JPS60100516A
(ja)
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
|
CA1256638A
(en)
|
1984-07-06 |
1989-06-27 |
Motoaki Tanaka |
Polymer and its production
|
|
JP2551756B2
(ja)
|
1985-05-07 |
1996-11-06 |
武田薬品工業株式会社 |
ポリオキシカルボン酸エステルおよびその製造法
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
US20050004186A1
(en)
|
2002-12-20 |
2005-01-06 |
Pfizer Inc |
MEK inhibiting compounds
|
|
ES2325440T3
(es)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
WO2005049021A1
(en)
|
2003-11-03 |
2005-06-02 |
Oy Helsinki Transplantation R & D Ltd |
Materials and methods for inhibiting neointimal hyperplasia
|
|
EP1758887A1
(en)
|
2004-05-14 |
2007-03-07 |
Pfizer Products Incorporated |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
US20060069110A1
(en)
|
2004-09-27 |
2006-03-30 |
Andersen Denise L |
Substituted heterocyclic compounds and methods of use
|
|
MY169441A
(en)
*
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
|
WO2006124874A2
(en)
|
2005-05-12 |
2006-11-23 |
Kalypsys, Inc. |
Inhibitors of b-raf kinase
|
|
WO2006129100A1
(en)
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
|
WO2007028445A1
(en)
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
|
DK2089369T3
(da)
|
2006-10-19 |
2011-05-09 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
|
|
DE102007010801A1
(de)
|
2007-03-02 |
2008-09-04 |
Bayer Cropscience Ag |
Diaminopyrimidine als Fungizide
|
|
US20100130496A1
(en)
|
2007-04-12 |
2010-05-27 |
F. Hoffmann-La Roche Ag |
Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
|
|
WO2008140421A2
(en)
*
|
2007-05-15 |
2008-11-20 |
S*Bio Pte Ltd |
Heterocycloalkyl substituted pyrimidine derivatives
|
|
US8461147B2
(en)
|
2007-12-03 |
2013-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
|
WO2009083185A2
(en)
|
2007-12-28 |
2009-07-09 |
Fovea Pharmaceuticals Sa |
Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders
|
|
CA2723205C
(en)
|
2008-04-16 |
2017-03-14 |
Portola Pharmaceuticals, Inc. |
2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
|
|
CA2722326A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
WO2009158431A2
(en)
|
2008-06-25 |
2009-12-30 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
CA2729121C
(en)
*
|
2008-06-30 |
2019-04-09 |
Centocor Ortho Biotech Inc. |
Differentiation of pluripotent stem cells
|
|
US20120114637A1
(en)
|
2009-05-04 |
2012-05-10 |
Santen Pharmaceutical Co., Ltd. |
Mtor pathway inhibitors for treating ocular disorders
|
|
WO2010146132A1
(en)
|
2009-06-18 |
2010-12-23 |
Cellzome Limited |
Sulfonamides and sulfamides as zap-70 inhibitors
|
|
WO2011084523A2
(en)
|
2009-12-15 |
2011-07-14 |
The Salk Institute For Biological Studies |
Ulk1 compositions, inhibitors, screening and methods of use
|
|
SG10201500124VA
(en)
|
2010-01-08 |
2015-03-30 |
Agency Science Tech & Res |
Methods and Compositions for Treating Cancer
|
|
WO2011133668A2
(en)
|
2010-04-20 |
2011-10-27 |
President And Fellows Of Harvard College |
Methods and compositions for the treatment of cancer
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
US20130252950A1
(en)
|
2010-09-23 |
2013-09-26 |
President And Fellows Of Harvard College |
Targeting mtor substrates in treating proliferative diseases
|
|
WO2012045195A1
(en)
|
2010-10-09 |
2012-04-12 |
Abbott Laboratories |
Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
|
|
US8691777B2
(en)
|
2011-01-27 |
2014-04-08 |
Emory University |
Combination therapy
|
|
US20120244209A1
(en)
|
2011-03-02 |
2012-09-27 |
Roth Jack A |
Tusc2 therapies
|
|
KR20130131461A
(ko)
|
2011-03-07 |
2013-12-03 |
폰다지오네 텔레톤 |
Tfeb 변종 및 그의 용도
|
|
US20140343128A1
(en)
|
2011-11-15 |
2014-11-20 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
|
|
US9073944B2
(en)
|
2012-02-21 |
2015-07-07 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
WO2014062621A1
(en)
|
2012-10-15 |
2014-04-24 |
Stc.Unm |
Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
US20150328193A1
(en)
|
2012-12-17 |
2015-11-19 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
|
CN103059030B
(zh)
|
2012-12-28 |
2015-04-29 |
北京师范大学 |
一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
|
|
HK1218249A1
(zh)
|
2013-01-25 |
2017-02-10 |
Rigel Pharmaceuticals, Inc. |
用於治疗炎症性肠道疾病的化合物和方法
|
|
BR112015030518A2
(pt)
|
2013-06-05 |
2017-08-29 |
Salk Inst For Biological Studi |
Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
|
|
CN106536503B
(zh)
|
2014-04-18 |
2019-09-06 |
北京澳合药物研究院有限公司 |
一种酪氨酸激酶抑制剂及其用途
|
|
US10053458B2
(en)
|
2014-06-17 |
2018-08-21 |
Korea Research Institute Of Chemical Technology |
Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
|
|
ES2914099T3
(es)
|
2014-08-25 |
2022-06-07 |
Salk Inst For Biological Studi |
Inhibidores novedosos de ULK1 y métodos de uso de los mismos
|
|
RS62017B1
(sr)
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitori i njihova upotreba
|
|
ES2899913T3
(es)
|
2014-09-24 |
2022-03-15 |
Salk Inst For Biological Studi |
Virus tumorales oncolíticos y métodos de uso
|
|
CN105524045B
(zh)
|
2014-10-22 |
2020-04-10 |
山东轩竹医药科技有限公司 |
四环类间变性淋巴瘤激酶抑制剂
|
|
WO2016090079A1
(en)
|
2014-12-05 |
2016-06-09 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN106188029B
(zh)
|
2015-05-05 |
2018-09-18 |
山东轩竹医药科技有限公司 |
二并环类间变性淋巴瘤激酶抑制剂
|
|
WO2016196393A2
(en)
|
2015-05-29 |
2016-12-08 |
Presage Biosciences, Inc. |
Autophagy-inhibiting compounds and uses thereof
|
|
US20170038387A1
(en)
|
2015-08-04 |
2017-02-09 |
Celgene Corporation |
Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
|
|
CN105801603B
(zh)
|
2016-04-13 |
2018-10-02 |
成都倍特药业有限公司 |
一种具有大环结构的alk抑制剂及其制备方法
|
|
CA3040173A1
(en)
|
2016-10-18 |
2018-04-26 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
|
|
US11180482B2
(en)
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
|
JP6684700B2
(ja)
|
2016-12-26 |
2020-04-22 |
アイシン精機株式会社 |
乗員検知装置
|
|
EP3620457A4
(en)
|
2017-05-02 |
2021-01-06 |
Korea Research Institute of Chemical Technology |
PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE
|
|
HUE065486T2
(hu)
|
2019-05-10 |
2024-05-28 |
Deciphera Pharmaceuticals Llc |
Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
|
|
HRP20231310T1
(hr)
|
2019-05-10 |
2024-02-02 |
Deciphera Pharmaceuticals, Llc |
Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
|
|
ES3072710T3
(en)
|
2019-06-17 |
2026-07-03 |
Deciphera Pharmaceuticals Llc |
Aminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
CA3171187A1
(en)
|
2020-02-14 |
2021-08-19 |
Salk Institute For Biological Studies |
Inhibitors of ulk1/2 and methods of using same
|
|
WO2021163633A1
(en)
|
2020-02-14 |
2021-08-19 |
Salk Institute For Biological Studies |
Mono and combination therapies with ulk1/2 inhibitors
|
|
WO2021216440A1
(en)
|
2020-04-20 |
2021-10-28 |
Tenova Pharmaceuticals Inc. |
Novel protein kinase inhibitors
|
|
US20230332243A1
(en)
|
2020-09-30 |
2023-10-19 |
Salk Institute For Biological Studies |
Patient selection biomarkers for treatment with ulk inhibitors
|